Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP
dc.contributor.author | Matsushita, Kunihiro | |
dc.contributor.author | Kaptoge, Stephen | |
dc.contributor.author | Hageman, Steven H J | |
dc.contributor.author | Sang, Yingying | |
dc.contributor.author | Ballew, Shoshana H. | |
dc.contributor.author | Grams, Morgan E. | |
dc.contributor.author | Surapaneni, Aditya | |
dc.contributor.author | Sun, Luanluan | |
dc.contributor.author | Arnlov, Johan | |
dc.contributor.author | Bozic, Milica | |
dc.contributor.author | Brenner, Hermann | |
dc.contributor.author | Brunskill, Nigel J. | |
dc.contributor.author | Chang, Alex R. | |
dc.contributor.author | Chinnadurai, Rajkumar | |
dc.contributor.author | Cirillo, Massimo | |
dc.contributor.author | Correa, Adolfo | |
dc.contributor.author | Ebert, Natalie | |
dc.contributor.author | Eckardt, Kai-Uwe | |
dc.contributor.author | Gansevoort, Ron T. | |
dc.contributor.author | Gutierrez, Orlando | |
dc.contributor.author | Hadaegh, Farzad | |
dc.contributor.author | He, Jiang | |
dc.contributor.author | Hwang, Shih-Jen | |
dc.contributor.author | Jafar, Tazeen H. | |
dc.contributor.author | Jassal, Simerjot K. | |
dc.contributor.author | Kayama, Takamasa | |
dc.contributor.author | Kovesdy, Csaba P. | |
dc.contributor.author | Landman, Gijs W. | |
dc.contributor.author | Levey, Andrew S. | |
dc.contributor.author | Lloyd-Jones, Donald M. | |
dc.contributor.author | Major, Rupert W. | |
dc.contributor.author | Miura, Katsuyuki | |
dc.contributor.author | Muntner, Paul | |
dc.contributor.author | Nadkarni, Girish N. | |
dc.contributor.author | Nowak, Christoph | |
dc.contributor.author | Ohkubo, Takayoshi | |
dc.contributor.author | Pena, Michelle J. | |
dc.contributor.author | Polkinghorne, Kevan R. | |
dc.contributor.author | Sairenchi, Toshimi | |
dc.contributor.author | Schaeffner, Elke | |
dc.contributor.author | Schneider, Markus P. | |
dc.contributor.author | Shalev, Varda | |
dc.contributor.author | Shlipak, Michael G. | |
dc.contributor.author | Solbu, Marit Dahl | |
dc.contributor.author | Stempniewicz, Nikita | |
dc.contributor.author | Tollitt, James | |
dc.contributor.author | Valdivielso, José M | |
dc.contributor.author | van der Leeuw, Joep | |
dc.contributor.author | Wang, Angela Yee-Moon | |
dc.contributor.author | Wen, Chi-Pang | |
dc.contributor.author | Woodward, Mark | |
dc.contributor.author | Yamagishi, Kazumasa | |
dc.contributor.author | Yatsuya, Hiroshi | |
dc.contributor.author | Zhang, Luxia | |
dc.contributor.author | Dorresteijn, Jannick A N | |
dc.contributor.author | Di Angelantonio, Emanuele | |
dc.contributor.author | Visseren, Frank L J | |
dc.contributor.author | Pennells, Lisa | |
dc.contributor.author | Coresh, Josef | |
dc.date.accessioned | 2024-02-12T12:26:35Z | |
dc.date.available | 2024-02-12T12:26:35Z | |
dc.date.issued | 2022-08-16 | |
dc.description.abstract | Aims - The 2021 European Society of Cardiology (ESC) guideline on cardiovascular disease (CVD) prevention categorizes moderate and severe chronic kidney disease (CKD) as high and very-high CVD risk status regardless of other factors like age and does not include estimated glomerular filtration rate (eGFR) and albuminuria in its algorithms, systemic coronary risk estimation 2 (SCORE2) and systemic coronary risk estimation 2 in older persons (SCORE2-OP), to predict CVD risk. We developed and validated an ‘Add-on’ to incorporate CKD measures into these algorithms, using a validated approach.<p> <p>Methods - In 3,054 840 participants from 34 datasets, we developed three Add-ons [eGFR only, eGFR + urinary albumin-to-creatinine ratio (ACR) (the primary Add-on), and eGFR + dipstick proteinuria] for SCORE2 and SCORE2-OP. We validated C-statistics and net reclassification improvement (NRI), accounting for competing risk of non-CVD death, in 5,997 719 participants from 34 different datasets.<p> <p>Results - In the target population of SCORE2 and SCORE2-OP without diabetes, the CKD Add-on (eGFR only) and CKD Add-on (eGFR + ACR) improved C-statistic by 0.006 (95%CI 0.004–0.008) and 0.016 (0.010–0.023), respectively, for SCORE2 and 0.012 (0.009–0.015) and 0.024 (0.014–0.035), respectively, for SCORE2-OP. Similar results were seen when we included individuals with diabetes and tested the CKD Add-on (eGFR + dipstick). In 57 485 European participants with CKD, SCORE2 or SCORE2-OP with a CKD Add-on showed a significant NRI [e.g. 0.100 (0.062–0.138) for SCORE2] compared to the qualitative approach in the ESC guideline.<p> <p>Conclusion - Our Add-ons with CKD measures improved CVD risk prediction beyond SCORE2 and SCORE2-OP. This approach will help clinicians and patients with CKD refine risk prediction and further personalize preventive therapies for CVD. | en_US |
dc.identifier.citation | Matsushita, Kaptoge, Hageman, Sang, Ballew, Grams, Surapaneni, Sun, Arnlov, Bozic, Brenner, Brunskill, Chang, Chinnadurai, Cirillo, Correa, Ebert, Eckardt, Gansevoort, Gutierrez, Hadaegh, He, Hwang, Jafar, Jassal, Kayama, Kovesdy, Landman, Levey, Lloyd-Jones, Major, Miura, Muntner, Nadkarni, Nowak, Ohkubo, Pena, Polkinghorne, Sairenchi, Schaeffner, Schneider, Shalev, Shlipak, Solbu, Stempniewicz, Tollitt, Valdivielso, van der Leeuw, Wang, Wen, Woodward, Yamagishi, Yatsuya, Zhang, Dorresteijn, Di Angelantonio, Visseren, Pennells, Coresh. Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP. European Journal of Preventive Cardiology (EJPC). 2023;30(1):8-16 | en_US |
dc.identifier.cristinID | FRIDAID 2138757 | |
dc.identifier.doi | 10.1093/eurjpc/zwac176 | |
dc.identifier.issn | 2047-4873 | |
dc.identifier.issn | 2047-4881 | |
dc.identifier.uri | https://hdl.handle.net/10037/32910 | |
dc.language.iso | eng | en_US |
dc.publisher | Oxford University Press | en_US |
dc.relation.journal | European Journal of Preventive Cardiology (EJPC) | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2023 The Author(s) | en_US |
dc.title | Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP | en_US |
dc.type.version | acceptedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |